GlassScriptPhysician profile
Sierra Purcell
NPI 1699412825
$7,951.75
in general payments reported to CMS, 2019-2025
22 companies · $2,386 in 2025
The $2,386 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $335 · 2023: $1,783 · 2024: $3,448 · 2025: $2,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,616.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,800.29 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,333.11 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $992.60 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $481.44 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $450.31 | 2023-2025 | Auvelity |
| Lundbeck LLC | $422.60 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $408.30 | 2024-2025 | Spravato |
| Neos Therapeutics, LP | $337.45 | 2023-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $322.00 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $275.15 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $249.64 | 2023-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $169.62 | 2023-2025 | Wellbutrin, Aplenzin |
| Teva Pharmaceuticals USA, INC. | $124.79 | 2023-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $120.34 | 2023 | Dyanavel Xr |
| Alkermes, INC. | $103.75 | 2023-2024 | Lybalvi, Aristada |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $89.70 | 2025 | Jornay Pm |
| Corium, LLC | $73.18 | 2023-2025 | Azstarys |
| Almatica Pharma LLC | $69.56 | 2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $55.12 | 2023-2025 | Ingrezza |
| Noven Therapeutics, LLC | $36.20 | 2023 | Secuado, Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $18.32 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sierra Purcell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.